Pharmaceutical composition exhibiting anti-tumor activity, method for treating patient suffering from cancer and method for inhibiting tumor growth

Abstract

A pharmaceutical composition exhibiting anti-tumor activity is provided. The pharmaceutical composition comprises para-toluenesulfonamide (PTS) and a pharmaceutically acceptable carrier. The pharmaceutical composition is used for treating squamous-cell carcinoma. The present invention further provides a method for treating a patient suffering from cancer and a method for inhibiting tumor growth.

1 . A pharmaceutical composition exhibiting anti-tumor activity, wherein the pharmaceutical composition comprises para-toluenesulfonamide (PTS) and a pharmaceutically acceptable carrier, and the pharmaceutical composition is used for treating squamous-cell carcinoma. 
     
     
         2 . The pharmaceutical composition exhibiting anti-tumor activity according to  claim 1 , wherein a concentration of PTS is between 2.5 μmol/l and 80 μmol/l. 
     
     
         3 . The pharmaceutical composition exhibiting anti-tumor activity according to  claim 1 , wherein the concentration of PTS is between 10 μmol/l and 20 μmol/l. 
     
     
         4 . The pharmaceutical composition exhibiting anti-tumor activity according to  claim 1 , wherein PTS has a selectivity with respect to treated cancer cells and normal cells. 
     
     
         5 . The pharmaceutical composition exhibiting anti-tumor activity according to  claim 4 , wherein the selectivity is determined by a suppression ratio, which is “cancer cell suppression %/normal cell suppression %”, and wherein the suppression ratio is 1.8˜5. 
     
     
         6 . The pharmaceutical composition exhibiting anti-tumor activity according to  claim 1 , wherein PTS activates apoptosis and necrosis to induce cancer cells death. 
     
     
         7 . The pharmaceutical composition exhibiting anti-tumor activity according to  claim 6 , wherein cancer cells death is triggered through ATP synthesis pathway of mitochondria. 
     
     
         8 . A method for treating a patient suffering from cancer, comprising:
 administering a pharmaceutical composition to a patient with squamous-cell carcinoma, wherein the pharmaceutical composition comprises para-toluenesulfonamide (PTS) and a pharmaceutically acceptable carrier.   
     
     
         9 . The method for treating a patient suffering from cancer according to  claim 8 , wherein a concentration of PTS is between 2.5 μmol/l and 80 μmol/l. 
     
     
         10 . The method for treating a patient suffering from cancer according to  claim 9 , wherein the concentration of PTS is between 10 μmol/l and 20 μmol/l. 
     
     
         11 . The method for treating a patient suffering from cancer according to  claim 8 , wherein after administering the pharmaceutical composition, an intracellular concentration of PTS in cancer cells is greater than an intracellular concentration of PTS in normal cells. 
     
     
         12 . The method for treating a patient suffering from cancer according to  claim 11 , wherein after administering the pharmaceutical composition, the intracellular concentration of PTS in cancer cells is 8˜12 folds greater than the intracellular concentration of PTS in normal cells. 
     
     
         13 . The method for treating a patient suffering from cancer according to  claim 8 , wherein PTS activates apoptosis and necrosis to induce cancer cells death. 
     
     
         14 . The method for treating a patient suffering from cancer according to  claim 13 , wherein cancer cells death is triggered through ATP synthesis pathway of mitochondria. 
     
     
         15 . A method for inhibiting cancer cells growth, comprising:
 providing a target body, comprising plural cancer cells comprising squamous-cell carcinoma; and   supplying a composition to the target body, wherein the composition comprises para-toluenesulfonamide (PTS) at a concentration between 2.5 μmol/l and 80 μmol/l.   
     
     
         16 . (canceled) 
     
     
         17 . The method for inhibiting cancer cells growth according to  claim 15 , wherein the concentration of PTS is between 10 μmol/l and 20 μmol/l. 
     
     
         18 . The method for inhibiting cancer cells growth according to  claim 15 , wherein the target body further comprises normal cells and PTS selectively inhibits the cancer cells without affecting normal cells. 
     
     
         19 . The method for inhibiting cancer cells growth according to  claim 15 , wherein PTS activates apoptosis and necrosis to induce cancer cells death. 
     
     
         20 . The method for inhibiting cancer cells growth according to  claim 19 , wherein cancer cells death is triggered through ATP synthesis pathway of mitochondria.